PL2528922T3 - Związki poliheterocykliczne jako inhibitory hcv - Google Patents

Związki poliheterocykliczne jako inhibitory hcv

Info

Publication number
PL2528922T3
PL2528922T3 PL11736639T PL11736639T PL2528922T3 PL 2528922 T3 PL2528922 T3 PL 2528922T3 PL 11736639 T PL11736639 T PL 11736639T PL 11736639 T PL11736639 T PL 11736639T PL 2528922 T3 PL2528922 T3 PL 2528922T3
Authority
PL
Poland
Prior art keywords
hcv inhibitors
polyheterocyclic compounds
polyheterocyclic
compounds
hcv
Prior art date
Application number
PL11736639T
Other languages
English (en)
Inventor
Zheng-Yun J Zhan
Original Assignee
Ab Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ab Pharma Ltd filed Critical Ab Pharma Ltd
Publication of PL2528922T3 publication Critical patent/PL2528922T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL11736639T 2010-01-27 2011-01-27 Związki poliheterocykliczne jako inhibitory hcv PL2528922T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201010101403 2010-01-27
EP11736639.3A EP2528922B1 (en) 2010-01-27 2011-01-27 Polyheterocyclic compounds as hcv inhibitors
PCT/CN2011/070702 WO2011091757A1 (en) 2010-01-27 2011-01-27 Polyheterocyclic compounds highly potent as hcv inhibitors

Publications (1)

Publication Number Publication Date
PL2528922T3 true PL2528922T3 (pl) 2018-01-31

Family

ID=44309417

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11736639T PL2528922T3 (pl) 2010-01-27 2011-01-27 Związki poliheterocykliczne jako inhibitory hcv

Country Status (20)

Country Link
US (2) US8653025B2 (pl)
EP (1) EP2528922B1 (pl)
JP (1) JP5833022B2 (pl)
KR (1) KR101781789B1 (pl)
CN (1) CN102140100B (pl)
AU (1) AU2011209051B2 (pl)
BR (1) BR112012018897A2 (pl)
CA (1) CA2788155C (pl)
CR (1) CR20120440A (pl)
ES (1) ES2644804T3 (pl)
IL (1) IL221123A (pl)
MX (1) MX344373B (pl)
MY (1) MY160222A (pl)
NZ (1) NZ601629A (pl)
PE (1) PE20121526A1 (pl)
PL (1) PL2528922T3 (pl)
RU (1) RU2535664C2 (pl)
SG (1) SG182737A1 (pl)
WO (1) WO2011091757A1 (pl)
ZA (1) ZA201206410B (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011268498A1 (en) 2010-06-24 2013-01-31 Genoscience Pharma Sas Treatment of hepatitis C virus related diseases using hydroxychloroquine or a combination of hydroxychloroquine and an anti-viral agent
WO2012061248A2 (en) 2010-11-01 2012-05-10 Rfs Pharma, Llc Novel specific hcv ns3 protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2857705A1 (en) 2011-06-16 2012-12-20 AB Pharma Ltd. Macrocyclic heterocyclic compounds for inhibiting hepatitis c virus and preparation and use thereof
US8912141B2 (en) 2011-06-23 2014-12-16 Panmed Ltd. Treatment of hepatitis C virus
US9040479B2 (en) 2012-01-12 2015-05-26 Cocrystal Pharma, Inc. HCV NS3 protease inhibitors
CN103570605B (zh) * 2012-08-01 2015-08-05 上海迪赛诺药业有限公司 特拉匹韦及其中间体的制备方法
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
WO2014070964A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014071007A1 (en) 2012-11-02 2014-05-08 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
WO2014137869A1 (en) 2013-03-07 2014-09-12 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CN104557954A (zh) * 2013-10-16 2015-04-29 上海唐润医药科技有限公司 抗hcv的大环化合物
CN105315261A (zh) * 2014-08-04 2016-02-10 正大天晴药业集团股份有限公司 Hcv ns3蛋白酶抑制剂的钠盐
CN105859748B (zh) * 2015-02-05 2018-06-08 爱博新药研发(上海)有限公司 多环化合物钠盐及其多晶型、制备方法及应用
US10441189B2 (en) * 2015-12-15 2019-10-15 International Business Machines Corporation High definition EEG
CN107043405B (zh) * 2016-02-05 2021-11-19 爱博新药研发(上海)有限公司 多环杂环化合物的晶型、其制备方法、应用及组合物
CN107266529A (zh) * 2016-04-08 2017-10-20 上海长森药业有限公司 一类抑制丙肝病毒的大环状杂环化合物及其制备和用途
CN106366089B (zh) * 2016-08-19 2019-06-11 爱斯特（成都）生物制药股份有限公司 二氢异吲哚衍生物及其类似物的制备方法
WO2018050631A1 (en) * 2016-09-13 2018-03-22 Haplogen Gmbh Antiviral compounds
WO2018209667A1 (zh) * 2017-05-19 2018-11-22 爱博新药研发(上海)有限公司 多环杂环化合物的晶型、其制备方法、应用及组合物
CR20200553A (es) 2018-04-18 2021-04-08 Constellation Pharmaceuticals Inc Moduladores de enzimas modificadoras de metilo, composiciones y usos de estos
CN120097995A (zh) 2018-05-21 2025-06-06 星座制药公司 甲基修饰酶的调节剂、其组合物和用途
CN110041262B (zh) 2019-01-02 2020-03-27 成都开美思商务信息咨询中心(有限合伙) 氮杂环卡宾配体及其钌催化剂、制备方法和应用
WO2021016414A1 (en) 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1599907A (en) * 1977-04-26 1981-10-07 Glaxo Lab Ltd Isoindolines
NZ227011A (en) 1987-11-18 1992-03-26 Chiron Corp Non-a, non-b-hepatitis (hepatitis c) antigens, proteins, nucleotide sequences, vaccines and kits
JPH0395115A (ja) * 1989-06-15 1991-04-19 Taisho Pharmaceut Co Ltd 鎭咳剤
FR2654726B1 (fr) * 1989-11-23 1992-02-14 Rhone Poulenc Sante Nouveaux derives de l'isoindolone et leur preparation.
DK26793D0 (da) * 1993-03-10 1993-03-10 Novo Nordisk As Benzofuranyl- eller dihydrobenzofuranyl-substituerede tricycliske benzazepiner, der anvendelse og fremstilling
US5990276A (en) 1996-05-10 1999-11-23 Schering Corporation Synthetic inhibitors of hepatitis C virus NS3 protease
AP1019A (en) 1996-10-18 2001-10-16 Vertex Pharma Inhibitors of serinre proteases, particularly hepatitis C virus NS3 protease.
GB9707659D0 (en) 1997-04-16 1997-06-04 Peptide Therapeutics Ltd Hepatitis C NS3 Protease inhibitors
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
ES2241157T3 (es) 1997-08-11 2005-10-16 Boehringer Ingelheim (Canada) Ltd. Peptidos inhibidores de la hepatitis c.
DK1066247T3 (da) 1998-03-31 2007-04-02 Vertex Pharma Inhibitorer af serinproteaser, især hepatitis C virus NS3 protease
GB9812523D0 (en) 1998-06-10 1998-08-05 Angeletti P Ist Richerche Bio Peptide inhibitors of hepatitis c virus ns3 protease
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN100352819C (zh) 2002-01-23 2007-12-05 先灵公司 作为ns3－丝氨酸蛋白酶抑制剂的脯氨酸化合物用于制备治疗丙型肝炎病毒感染的药物
HRP20130098T1 (hr) * 2003-10-14 2013-02-28 F. Hoffmann - La Roche Ag MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a
CN1889970B (zh) * 2003-10-14 2012-06-13 F·霍夫曼-罗须公司 作为hcv复制抑制剂的巨环羧酸和酰基磺酰胺
CN1938311A (zh) * 2004-03-30 2007-03-28 因特蒙公司 作为病毒复制抑制剂的大环化合物
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US20060111385A1 (en) * 2004-11-22 2006-05-25 Molino Bruce F Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof
AR057456A1 (es) 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
WO2007111866A2 (en) * 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
WO2007115409A1 (en) * 2006-04-10 2007-10-18 Painceptor Pharma Corporation Compositions and methods for modulating gated ion channels
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
BRPI0718161A2 (pt) 2006-10-27 2013-11-26 Merck & Co Inc Composto, composição farmacêutica, e, uso do composto.
US8377874B2 (en) 2006-10-27 2013-02-19 Merck Sharp & Dohme Corp. HCV NS3 protease inhibitors
BRPI0718798A2 (pt) 2006-11-17 2013-12-03 Tibotec Pharm Ltd Inibidores macrocíclicos de vírus da hepatite c
TWI423968B (zh) 2007-02-01 2014-01-21 Tibotec Pharm Ltd Ｈｃｖ巨環抑制劑之多晶形
DE602008001251D1 (de) 2007-02-01 2010-06-24 Tibotec Pharm Ltd Verfahren und zwischenprodukte zur herstellung eines makrozyklischen proteasehemmers von hcv
BRPI0807887A2 (pt) 2007-02-20 2014-06-17 Novartis Ag Compostos macrocíclicos como inibidores de hcv ns3 protease.
JP5241834B2 (ja) * 2007-07-19 2013-07-17 メルク・シャープ・アンド・ドーム・コーポレーション プロテインキナーゼ阻害剤としての複素環アミド化合物
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
CL2008003384A1 (es) 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
TWI487522B (zh) * 2007-12-21 2015-06-11 賽基艾維洛米斯研究股份有限公司 Ｈｃｖ蛋白酶抑制劑及其用途（一）
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
WO2009134624A1 (en) 2008-04-28 2009-11-05 Merck & Co., Inc. Hcv ns3 protease inhibitors
WO2010033466A1 (en) 2008-09-16 2010-03-25 Phenomix Corporation Macrocyclic inhibitors of hepatitis c protease
AR074758A1 (es) 2008-12-22 2011-02-09 Gilead Sciences Inc Compuestos macrociclicos antivirales
TW201031661A (en) * 2009-02-17 2010-09-01 Targacept Inc Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
MX2013004655A (es) * 2010-10-26 2013-08-27 Presidio Pharmaceuticals Inc Inhibidores del virus de la hepatitis c.

Also Published As

Publication number Publication date
SG182737A1 (en) 2012-08-30
ES2644804T3 (es) 2017-11-30
PE20121526A1 (es) 2012-12-06
EP2528922A1 (en) 2012-12-05
MX344373B (es) 2016-12-13
WO2011091757A1 (en) 2011-08-04
AU2011209051B2 (en) 2015-01-15
KR101781789B1 (ko) 2017-09-26
RU2012136592A (ru) 2014-02-27
US20110183895A1 (en) 2011-07-28
MX2012008745A (es) 2013-01-18
AU2011209051A1 (en) 2012-08-23
US8653025B2 (en) 2014-02-18
US20140005104A1 (en) 2014-01-02
US8815796B2 (en) 2014-08-26
CN102140100A (zh) 2011-08-03
ZA201206410B (en) 2013-05-29
CA2788155A1 (en) 2011-08-04
EP2528922A4 (en) 2013-10-16
JP2013518067A (ja) 2013-05-20
IL221123A (en) 2016-12-29
CN102140100B (zh) 2014-06-11
NZ601629A (en) 2014-11-28
JP5833022B2 (ja) 2015-12-16
MY160222A (en) 2017-02-28
RU2535664C2 (ru) 2014-12-20
BR112012018897A2 (pt) 2017-10-03
CR20120440A (es) 2013-02-13
CA2788155C (en) 2018-04-24
KR20120139706A (ko) 2012-12-27
EP2528922B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
PL2528922T3 (pl) Związki poliheterocykliczne jako inhibitory hcv
EP2528926A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
SI2563771T1 (sl) Spojine inhibitorjev metaloencimov
GB201005589D0 (en) Novel compounds
GB201004311D0 (en) New enzyme inhibitor compounds
GB201007203D0 (en) Novel compounds
IL224178A (en) Heterogeneous history of cervix as hcv inhibitors
EP2504343A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
GB201012686D0 (en) Novel compounds
EP2632903A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2651905A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
GB201007791D0 (en) Novel compounds
GB201004308D0 (en) New inhibitor compounds
GB201009514D0 (en) Novel heterocyclic compounds
GB201021416D0 (en) Novel heterocyclic compounds
GB201008985D0 (en) Novel compounds
GB201002097D0 (en) Novel compounds
GB201006128D0 (en) Novel compounds
GB201006124D0 (en) Novel compounds
GB201006846D0 (en) Novel compounds
GB201002828D0 (en) Novel compounds
GB201002827D0 (en) Novel compounds
GB201002821D0 (en) Novel compounds
GB201002818D0 (en) Novel compounds
GB201002811D0 (en) Novel compounds